Vanda Pharmaceuticals SG&A Expense (Quarterly) Insights

Vanda Pharmaceuticals Inc (VNDA)

5.41 -0.07 (-1.28%) USD | NASDAQ | May 20, 11:16

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2005. Upgrade now.

Date	Value
March 31, 2024	30.08M
December 31, 2023	23.61M
September 30, 2023	24.77M
June 30, 2023	28.40M
March 31, 2023	36.10M
December 31, 2022	32.78M
September 30, 2022	29.85M
June 30, 2022	33.00M
March 31, 2022	40.85M
December 31, 2021	33.45M
September 30, 2021	32.46M
June 30, 2021	28.35M
March 31, 2021	29.80M
December 31, 2020	35.57M
September 30, 2020	34.00M
June 30, 2020	33.92M
March 31, 2020	37.02M
December 31, 2019	37.02M
September 30, 2019	30.22M
June 30, 2019	31.47M
March 31, 2019	31.03M
December 31, 2018	24.92M
September 30, 2018	26.05M
June 30, 2018	27.96M
March 31, 2018	26.82M

Date	Value
December 31, 2017	31.05M
September 30, 2017	31.12M
June 30, 2017	31.37M
March 31, 2017	30.30M
December 31, 2016	23.91M
September 30, 2016	21.91M
June 30, 2016	24.68M
March 31, 2016	29.29M
December 31, 2015	28.88M
September 30, 2015	18.46M
June 30, 2015	18.39M
March 31, 2015	18.81M
December 31, 2014	17.32M
September 30, 2014	11.29M
June 30, 2014	28.14M
March 31, 2014	27.89M
December 31, 2013	9.928M
September 30, 2013	5.741M
June 30, 2013	5.26M
March 31, 2013	4.153M
December 31, 2012	3.86M
September 30, 2012	3.147M
June 30, 2012	3.601M
March 31, 2012	3.909M
December 31, 2011	3.345M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

23.61M

Minimum

Dec 2023

40.85M

Maximum

Mar 2022

32.14M

Average

32.62M

Median

SG&A Expense (Quarterly) Benchmarks